Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3389/fimmu.2022.907341

http://scihub22266oqcxt.onion/10.3389/fimmu.2022.907341
suck pdf from google scholar
35711442!9196174!35711442
unlimited free pdf from europmc35711442    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid35711442      Front+Immunol 2022 ; 13 (ä): 907341
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence #MMPMID35711442
  • Yagovkina NV; Zheleznov LM; Subbotina KA; Tsaan AA; Kozlovskaya LI; Gordeychuk IV; Korduban AK; Ivin YY; Kovpak AA; Piniaeva AN; Shishova AA; Shustova EY; Khapchaev YK; Karganova GG; Siniugina AA; Pomaskina TV; Erovichenkov AA; Chumakov K; Ishmukhametov AA
  • Front Immunol 2022[]; 13 (ä): 907341 PMID35711442show ga
  • BACKGROUND: Effective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could significantly alter its course and save countless lives. Live attenuated vaccines (LAVs) were shown to induce non-specific protection against a broad spectrum of off-target pathogens by stimulating innate immune responses. The purpose of this study was to evaluate the effect of immunization with bivalent Oral Poliovirus Vaccine (bOPV) on the incidence of COVID-19 and other acute respiratory infections (ARIs). METHODS AND FINDINGS: A randomized parallel-group comparative study was conducted in Kirov Medical University. 1115 healthy volunteers aged 18 to 65 were randomized into two equal groups, one of which was immunized orally with a single dose of bOPV "BiVac Polio" and another with placebo. The study participants were monitored for three months for respiratory illnesses including COVID-19. The endpoint was the incidence of acute respiratory infections and laboratory confirmed COVID-19 in both groups during 3 months after immunization. The number of laboratory-confirmed cases of COVID-19 was significantly lower in the vaccinated group than in placebo (25 cases vs. 44, p=0.036). The difference between the overall number of clinically diagnosed respiratory illnesses in the two groups was not statistically significant. CONCLUSIONS: Immunization with bOPV reduced the number of laboratory-confirmed COVID-19 cases, consistent with the original hypothesis that LAVs induce non-specific protection against off-target infections. The findings are in line with previous observations of the protective effects of OPV against seasonal influenza and other viral and bacterial pathogens. The absence of a statistically significant effect on the total number of ARIs may be due to the insufficient number of participants and heterogeneous etiology of ARIs. OPV could be used to complement specific coronavirus vaccines, especially in regions of the world where the vaccines are unavailable, and as a stopgap measure for urgent response to future emerging infections. Clinical trial registration number NCT05083039 at clinicaltrals.gov https://clinicaltrials.gov/ct2/show/NCT05083039?term=NCT05083039&draw=2&rank=1.
  • |*COVID-19/epidemiology/prevention & control[MESH]
  • |*Poliomyelitis/epidemiology/prevention & control[MESH]
  • |*Respiratory Tract Infections[MESH]
  • |Humans[MESH]
  • |Incidence[MESH]
  • |Poliovirus Vaccine, Oral[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box